Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy

Recruiting now · Phase 4

Conditions studied: Tonsillectomy With or Without Adenoidectomy

In brief

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.

Key facts

Study ID

NCT07118579

Run by

Tongji Hospital

People needed

114

Starts

2025-09-23

Expected to finish

2026-08-01

Last updated by the study team

2025-11-21

Who can join

Age: 2 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 2-12 years
• ASA physical status I-II
• Body mass index (BMI): 14-28 kg/m²
• Scheduled for elective tonsillectomy with or without adenoidectomy
• Signed informed consent by legal guardian(s) and assent by children (≥8 years old)

You may not qualify if…

• History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA)
• Previous episodes of significant PRAEs
• Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol)
• Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic/renal function
• Preoperative moderate-to-severe respiratory infections requiring surgery postponement
• Recent participation in other clinical trials

Where it is running

• Tongji Hospital — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.